Mometasone

The selected cream treats inflammatory and itchy corticosteroid-responsive dermatoses from age 2. The OTC nasal spray relieves nasal allergy symptoms from age 2. The current selected prescription nasal label instead lists seasonal-rhinitis prophylaxis from age 12 and chronic rhinosinusitis with nasal polyps in adults 18 and older. Historical pediatric rhinitis studies in the Rx label do not expand its current indication list.

Asmanex HFA is an asthma maintenance inhaler from age 5; Twisthaler from age 4. Neither relieves acute bronchospasm. Nasal sprays and skin cream cannot substitute for an asthma inhaler. This profile covers these five representative single-ingredient products; other topical vehicles, devices, and combination therapies need their own labels.

Cream: thin film once daily; stop when controlled and reassess if no improvement within 2 weeks. Avoid face, groin, axillae, eyes, diaper area, and occlusion unless directed; wash hands. Nasal doses below are sprays into EACH nostril, using 50 mcg/spray. Shake before use.

Age ≥12: start two 100 mcg inhalations twice daily when not already using an inhaled corticosteroid; prior treatment/severity determines other starts. Chronic oral-steroid users start two 200 mcg inhalations twice daily. If inadequate after 2 weeks, consider escalation; maximum two 200 mcg inhalations twice daily (800 mcg/day). Age 5–11: two 50 mcg inhalations twice daily, maximum 200 mcg/day. Titrate to the lowest effective dose after stability.

Use the labeled 110/220 mcg strength convention for this dosing table, not the 100/200 mcg mouthpiece dose. Once-daily doses are taken in the evening. Taper systemic steroids carefully with objective airflow and adrenal monitoring; never convert HFA to DPI by simply matching a printed number.

HFA: shake before each inhalation; prime with four sprays initially and after more than 5 days unused. Use only its own actuator. Twisthaler: hold upright to remove cap, exhale away from device, inhale rapidly/deeply, wipe mouthpiece dry, and close until it clicks; do not wash or breathe out into it. Rinse mouth and spit after either asthma inhaler. Rx nasal: initially prime ten times or until mist; after more than 1 week unused reprime twice or until mist. OTC nasal: follow its mist-based insert priming after a new bottle, a week unused, or cleaning; do not use a sharp object to unclog.

Cream and Rx nasal spray contraindicate component hypersensitivity. Both asthma devices contraindicate primary treatment of status asthmaticus/acute episodes requiring intensive measures and component hypersensitivity; Twisthaler additionally contraindicates milk-protein allergy because lactose contains traces of milk proteins. This is not a class-wide lactose-intolerance contraindication. OTC nasal directions prohibit use below age 2, for asthma, after unhealed nasal injury/surgery, or after product allergy.

The selected U.S. products do not have a boxed warning. Their adrenal, growth, infection, ocular, and acute-asthma limitations still require active management.

Cream may cause burning, itching, atrophy, irritation, or secondary infection. Nasal products may cause headache, epistaxis, local irritation, and reported hypersensitivity or septal injury. Inhalers may cause headache, upper respiratory symptoms, thrush, and reported hypersensitivity/asthma aggravation; spontaneous reports do not establish event frequency. Excess chronic exposure can cause hypercorticism and adrenal suppression. The Rx nasal/DPI labels describe observation as usually sufficient after acute overdose because systemic bioavailability is low; individual assessment remains necessary. OTC overdose directions advise medical help or Poison Control immediately.

HFA, DPI, and Rx nasal labels caution with strong inhibitors such as ketoconazole, ritonavir, cobicistat, or clarithromycin: systemic exposure and steroid effects can increase. Weigh benefit against risk and monitor. The OTC label asks for clinician/pharmacist review of HIV medicines, ketoconazole tablets, and other steroid therapy. No drug-interaction studies have been conducted with the selected cream; absence of studies is not proof of no interaction.

Replacing oral corticosteroids with an inhaler can unmask adrenal insufficiency or previously suppressed allergy. Arrange a supervised taper and a stress plan. For Twisthaler, the label says prednisone reduction no faster than 2.5 mg of the daily dose per week, beginning after at least 1 week of inhaler therapy; this is device-label guidance, not a universal taper for every patient or corticosteroid.

Cream has inadequate pregnancy data and uncertain milk transfer; assess benefit/risk. The current Rx nasal label describes minimal maternal absorption, fetal/infant exposure not expected, but insufficient pregnancy-outcome and direct milk data. Asmanex labels have no adequate controlled pregnancy studies and no direct milk/infant-effect data; uncontrolled asthma itself increases maternal/perinatal risk, so monitor and maintain control. OTC nasal spray directs consultation during pregnancy or breastfeeding.

Use only the product-specific approved age and regimen above. Cream safety beyond 3 weeks in children is not established; do not use for diaper dermatitis. Routinely follow child growth for nasal or inhaled steroid exposure and use the lowest effective dose. Older adults showed no overall label-reported efficacy/safety difference, though sensitivity may vary; HFA does not warrant age-based dose adjustment on available data.

Mometasone concentrations appear to rise with hepatic-impairment severity; the Rx nasal and inhaler labels do not establish a numeric adjustment. Renal effects are inadequately studied, not an established universal “no adjustment” rule. The topical label supplies no organ-based dosing algorithm, and liver failure raises adrenal-suppression risk. Assess systemic exposure and interactions in vulnerable patients.

Mometasone acts on glucocorticoid pathways to suppress inflammatory cells/mediators. The precise therapeutic mechanism is incompletely defined. Cream is medium potency in comparative vasoconstrictor testing. Inhaler benefit takes regular use, with maximal response after a week or longer; nasal relief may start within 12 hours but full benefit takes several days. In vitro receptor affinity does not establish interchangeability or clinical superiority.

Rx nasal bioavailability is below 1%; cream studies found approximately 0.4% absorbed after 8 hours on intact skin without occlusion, with greater absorption possible through diseased skin. Absorbed mometasone is highly protein bound and extensively metabolized by CYP3A4, with predominantly fecal/biliary elimination. HFA and DPI exposure differ, so route-specific absorption and half-life findings cannot support automatic dose conversion.

Assess asthma symptoms, rescue use, airflow, adherence, inhalation technique, thrush, growth, bone/eye risk, and adrenal symptoms during systemic-steroid transition. Check skin response, atrophy, infection, and high-exposure adrenal risk with cream. Inspect nasal mucosa during prolonged use and assess persistent bleeding or whistling. OTC allergy symptoms not improving within 7 days, severe facial pain, or thick discharge require stopping and clinician assessment.

Use the exact device daily and keep the prescribed rapid-relief medicine available for asthma. Seek prompt help for worsening/unresponsive asthma, severe allergy, vision change, severe bleeding, or infection exposure. Rinse and spit after inhaled doses; avoid sharing nasal bottles. Do not double missed OTC doses or increase any product beyond instructions. Tell clinicians about all steroid products and CYP3A4 inhibitors.

Selected cream is Bryant Ranch repackaged 15 g, NDC 71335-2873-1. Rx Apotex nasal bottle: 17 g, 120 sprays, NDC 60505-0830-1. OTC HyVee / Perrigo nasal bottle contains 120 sprays in a 17 mL package. Organon HFA 50/100/200 mcg each has 120 metered actuations, NDC 78206-111/112/113-01; Twisthaler 110 mcg has a 30-dose unit NDC 78206-115-01 and 220 mcg has 14/30/60/120-dose packages. These identities do not establish current stock or interchangeability.

Cream 0.1% contains 1 mg mometasone furoate/g. Both selected nasal sprays provide 50 mcg/spray. HFA provides 50, 100, or 200 mcg per actuation; only 50 mcg is the age 5–11 strength. Twisthaler labeled 110/220 mcg strengths deliver 100/200 mcg respectively from the mouthpiece; its age 4–11 regimen uses the labeled 110 mcg device. Twisthaler contains lactose with trace milk proteins; HFA does not carry that milk-protein contraindication.

Cream, nasal sprays, and HFA: 20–25°C; Twisthaler: 25°C with 15–30°C excursions permitted. Follow each label’s permitted excursions. Cream: avoid excessive heat. Rx nasal: protect from light and shake well. HFA: keep own actuator, do not remove canister, discard at counter zero, avoid fire/puncture/heat above 120°F; store mouthpiece down or horizontal after priming. Twisthaler: keep dry; discard 45 days after foil opening or when the final dose is inhaled at counter 00, whichever is first. Do not wash it.